Assignee
GILGAMESH PHARMACEUTICALS INC
US·6 granted patents·17 pending applications·7 citations·filing 2021–2025
Top patents by PatentIndex Score
23 records- 0194US11440879B2Methods of treating mood disordersGILGAMESH PHARMACEUTICALS INC·Filed 2021·Granted Sep 13, 2022·6 cites·2 claims
- 0287US2026055059A1Methods of treating mood disordersGILGAMESH PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 0386US11344510B2Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disordersGILGAMESH PHARMACEUTICALS INC·Filed 2021·Granted May 31, 2022·1 cites·2 claims
- 0483US2024351983A1Methods of treating mood disordersGILGAMESH PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0582US2024317683A1Methods of treating mood disordersGILGAMESH PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0679US12180158B1Crystalline fumarate salts of n-ethyl-2-(5-fluoro-1H-indol-3-yl)-n-methylethan-1-amineGILGAMESH PHARMACEUTICALS INC·Filed 2023·Granted Dec 31, 2024·0 cites·30 claims
- 0779US12157722B1Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amineGILGAMESH PHARMACEUTICALS INC·Filed 2023·Granted Dec 3, 2024·0 cites·10 claims
- 0876US2025115552A1Crystalline hydrochloride salts of n-ethyl-2-(5-fluoro-1h-indol-3-yl)-n-methylethan-1-amineGILGAMESH PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0972US2022241243A1Methods of treating mood disordersGILGAMESH PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1069US12129234B1Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amineGILGAMESH PHARMACEUTICALS INC·Filed 2023·Granted Oct 29, 2024·0 cites·30 claims
- 1167US12534425B2Phenalkylamines and methods of treating mood disordersGILGAMESH PHARMACEUTICALS INC·Filed 2021·Granted Jan 27, 2026·0 cites·20 claims
- 1264US2022409555A1Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disordersGILGAMESH PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1364US2025042851A1Crystalline salts of n-ethyl-(5-fluoro-1h-indol-3-yl)-n-methylethan-1-amineGILGAMESH PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1461US2025161264A1(ampar-pam)-nmda receptor antagonist combination therapy for treatment of mental conditions and disordersGILGAMESH PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1561US2025270173A1Pyridine derivatives for treating psychiatric disordersGILGAMESH PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1659US2024216339A1Methods of treating neuropsychiatric disordersGILGAMESH PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1758US2024390301A1Combinations of peripheral 5-ht2a receptor antagonists and central 5-ht2a receptor agonistsGILGAMESH PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1857US2023116703A1Novel ergolines and methods of treating mood disordersGILGAMESH PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1957US2024246911A1Novel tryptamines and methods of treating mood disordersGILGAMESH PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2056US2024368151A1Novel ergolines and methods of treating mood disordersGILGAMESH PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2155US2024166618A1Phenalkylamines and methods of making and using the sameGILGAMESH PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2253US2023322735A1Azetidinyl tryptamines and methods of treating psychiatric disordersGILGAMESH PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2348US2024300886A1Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disordersGILGAMESH PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →